oxonic acid has been researched along with Carcinoma, Ductal, Pancreatic in 33 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the efficacy and safety of nab-paclitaxel plus S-1 (nab-P/S) versus nab-paclitaxel plus gemcitabine (nab-P/G) as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC)." | 9.41 | Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. ( Lu, M; Peng, Z; Shen, L; Wang, X; Yuan, J; Zhou, J; Zong, Y, 2021) |
| "The objective of this study was to determine the recommended dose (RD) of a biweekly S-1, oxaliplatin, and irinotecan (SOXIRI) regimen in patients with unresectable pancreatic ductal adenocarcinoma." | 9.22 | Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. ( Akahori, T; Hirooka, S; Ikeda, N; Kinoshita, S; Kon, M; Kotsuka, M; Nagai, M; Nakajima, Y; Nishiwada, S; Ryota, H; Satoi, S; Sho, M; Tsuta, K; Yamaki, S; Yamamoto, T; Yanagimoto, H, 2016) |
| "To investigate the efficacy and safety of nab-paclitaxel plus S-1 (nab-P/S) versus nab-paclitaxel plus gemcitabine (nab-P/G) as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC)." | 5.41 | Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. ( Lu, M; Peng, Z; Shen, L; Wang, X; Yuan, J; Zhou, J; Zong, Y, 2021) |
| "The objective of this study was to determine the recommended dose (RD) of a biweekly S-1, oxaliplatin, and irinotecan (SOXIRI) regimen in patients with unresectable pancreatic ductal adenocarcinoma." | 5.22 | Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. ( Akahori, T; Hirooka, S; Ikeda, N; Kinoshita, S; Kon, M; Kotsuka, M; Nagai, M; Nakajima, Y; Nishiwada, S; Ryota, H; Satoi, S; Sho, M; Tsuta, K; Yamaki, S; Yamamoto, T; Yanagimoto, H, 2016) |
| "Nab-paclitaxel plus S1 was more efficient in terms of ORR and DCR than S1 monotherapy in elderly pancreatic ductal adenocarcinoma patients while the side effect was controllable with a higher probability of leukopenia." | 5.12 | Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patients: A meta-analysis. ( Chen, D; Chen, X; Chen, Y; Cui, S; Du, J; Gu, J; Lin, Z; Luo, H; Ma, C; Wang, C; Yang, L; Yin, M, 2021) |
| " According to the prescribed protocol of the clinical trial, statistical analyses included 57 phase 2 patients and 6 phase 1 patients who received the same dosage as in phase 2." | 2.90 | A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma. ( Doki, Y; Eguchi, H; Isohashi, F; Kashiwazaki, M; Mori, M; Nagano, H; Nakahira, S; Sakai, D; Shimizu, J; Takahashi, H; Takeda, Y, 2019) |
| " A total of 185 patients with inoperable or metastatic pancreatic cancer who were refractory or intolerant to standard primary chemotherapy with gemcitabine plus nab-paclitaxel will be allocated to secondary treatment either with placebo in combination with S-1 (the control group) or TLP0-001 in combination with S-1 (the investigational product group)." | 2.90 | A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy. ( Adachi, T; Akahori, T; Asahara, S; Endo, I; Fujii, T; Furukawa, M; Hakamada, K; Hara, K; Ioka, T; Katanuma, A; Katsuda, M; Kitano, M; Miyazawa, M; Nagano, H; Ohira, M; Ojima, T; Satoi, S; Sudo, K; Ueno, M; Yamada, S; Yamaue, H, 2019) |
| "Paclitaxel was administered i." | 2.84 | Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. ( Fujii, T; Honda, G; Isayama, H; Ishigami, H; Kodera, Y; Kon, M; Kurata, M; Mizuma, M; Motoi, F; Satoi, S; Takahara, N; Unno, M; Yamada, S; Yamamoto, T; Yanagimoto, H, 2017) |
| "However, pancreatic cancer is non-immunogenic, and single agent immunotherapies are unfavorable to its prognosis." | 1.62 | Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report. ( Ye, Y; Zheng, S, 2021) |
| "Lymph node metastasis was an independent risk factor for both locoregional (P < 0." | 1.62 | Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma. ( Hayami, S; Hirono, S; Kawai, M; Kitahata, Y; Kobayashi, R; Miyazawa, M; Okada, KI; Ueno, M; Yamaue, H, 2021) |
| "To investigate the predictive value of secreted protein acidic and rich in cysteine (SPARC) expression in patients with PDAC treated with adjuvant gemcitabine in combination with S-1 (adjuvant GS) or adjuvant gemcitabine alone (adjuvant G alone)." | 1.48 | The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone. ( Kondo, N; Murakami, Y; Nakagawa, N; Okano, K; Shintakuya, R; Sueda, T; Takahashi, S; Uemura, K, 2018) |
| "Fifty-two patients with pancreatic cancer who underwent surgical resection were enrolled in this study." | 1.40 | Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. ( Endo, I; Homma, Y; Ichikawa, Y; Matsuyama, R; Mori, R; Murakami, T; Nakagawa, K; Nakazawa, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 22 (66.67) | 24.3611 |
| 2020's | 11 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ye, Y | 1 |
| Zheng, S | 1 |
| Tomimaru, Y | 3 |
| Eguchi, H | 6 |
| Inoue, Y | 2 |
| Nagakawa, Y | 2 |
| Ohba, A | 2 |
| Takami, H | 2 |
| Unno, M | 4 |
| Yamamoto, T | 6 |
| Kawakatsu, S | 2 |
| Hayashi, T | 2 |
| Higuchi, R | 3 |
| Kitagawa, H | 2 |
| Hattori, S | 2 |
| Fujii, T | 4 |
| Hirooka, Y | 2 |
| Igarashi, H | 2 |
| Kitano, M | 3 |
| Kuroki, T | 2 |
| Masamune, A | 2 |
| Shimizu, Y | 2 |
| Tani, M | 2 |
| Tanno, S | 2 |
| Tsuji, Y | 2 |
| Yamaue, H | 4 |
| Satoi, S | 7 |
| Takeyama, Y | 2 |
| Takeda, Y | 2 |
| Takahashi, H | 1 |
| Nakahira, S | 1 |
| Kashiwazaki, M | 1 |
| Shimizu, J | 1 |
| Sakai, D | 2 |
| Isohashi, F | 2 |
| Nagano, H | 3 |
| Mori, M | 4 |
| Doki, Y | 4 |
| Matsuda, Y | 1 |
| Ohkubo, S | 1 |
| Nakano-Narusawa, Y | 1 |
| Fukumura, Y | 1 |
| Hirabayashi, K | 1 |
| Yamaguchi, H | 1 |
| Sahara, Y | 1 |
| Kawanishi, A | 1 |
| Takahashi, S | 3 |
| Arai, T | 1 |
| Kojima, M | 1 |
| Mino-Kenudson, M | 1 |
| Zong, Y | 1 |
| Yuan, J | 1 |
| Peng, Z | 1 |
| Lu, M | 1 |
| Wang, X | 1 |
| Shen, L | 1 |
| Zhou, J | 1 |
| Yan, X | 1 |
| Ning, ZY | 1 |
| Wang, P | 1 |
| Zhuang, LP | 1 |
| Xu, LT | 1 |
| Zhu, ZF | 1 |
| Sheng, J | 1 |
| Shen, YH | 1 |
| Hua, YQ | 1 |
| Meng, ZQ | 1 |
| Izumo, W | 1 |
| Furukawa, T | 1 |
| Yazawa, T | 1 |
| Uemura, S | 1 |
| Matsunaga, Y | 1 |
| Shiihara, M | 1 |
| Yamamoto, M | 1 |
| Liang, L | 1 |
| Ding, Y | 1 |
| Yu, Y | 1 |
| Liu, K | 1 |
| Rao, S | 1 |
| Ge, Y | 1 |
| Zeng, M | 1 |
| Li, B | 1 |
| Shen, S | 1 |
| You, S | 1 |
| Zhang, G | 1 |
| Gao, S | 1 |
| Shi, X | 1 |
| Wang, H | 1 |
| Yin, X | 1 |
| Xu, X | 1 |
| Guo, S | 1 |
| Jin, G | 1 |
| Hashimoto, D | 1 |
| Yamaki, S | 3 |
| Ishida, M | 1 |
| Ryota, H | 3 |
| Sakaguchi, T | 1 |
| Hirooka, S | 3 |
| Inoue, K | 2 |
| Sekimoto, M | 1 |
| Hirono, S | 1 |
| Kawai, M | 1 |
| Okada, KI | 1 |
| Miyazawa, M | 2 |
| Kitahata, Y | 1 |
| Kobayashi, R | 1 |
| Hayami, S | 1 |
| Ueno, M | 2 |
| Chen, Y | 1 |
| Gu, J | 1 |
| Yin, M | 1 |
| Wang, C | 1 |
| Chen, D | 1 |
| Yang, L | 1 |
| Chen, X | 1 |
| Lin, Z | 1 |
| Du, J | 1 |
| Cui, S | 1 |
| Ma, C | 1 |
| Luo, H | 1 |
| Okano, K | 2 |
| Suto, H | 1 |
| Oshima, M | 1 |
| Maeda, E | 1 |
| Yamamoto, N | 1 |
| Kakinoki, K | 1 |
| Kamada, H | 1 |
| Masaki, T | 1 |
| Shibata, T | 1 |
| Suzuki, Y | 1 |
| Shintakuya, R | 1 |
| Kondo, N | 1 |
| Murakami, Y | 1 |
| Uemura, K | 1 |
| Nakagawa, N | 1 |
| Sueda, T | 1 |
| Yamada, D | 2 |
| Iwagami, Y | 1 |
| Asaoka, T | 2 |
| Noda, T | 2 |
| Kawamoto, K | 3 |
| Gotoh, K | 2 |
| Kobayashi, S | 3 |
| Katsuda, M | 1 |
| Ojima, T | 1 |
| Katanuma, A | 1 |
| Hakamada, K | 1 |
| Sudo, K | 1 |
| Asahara, S | 1 |
| Endo, I | 2 |
| Hara, K | 1 |
| Yamada, S | 2 |
| Ioka, T | 1 |
| Ohira, M | 1 |
| Akahori, T | 2 |
| Furukawa, M | 1 |
| Adachi, T | 1 |
| Motoi, F | 2 |
| Ishida, K | 1 |
| Fujishima, F | 1 |
| Ottomo, S | 1 |
| Oikawa, M | 1 |
| Okada, T | 1 |
| Shimamura, H | 1 |
| Takemura, S | 1 |
| Ono, F | 1 |
| Akada, M | 1 |
| Nakagawa, K | 2 |
| Katayose, Y | 1 |
| Egawa, S | 1 |
| Wada, H | 2 |
| Hama, N | 1 |
| Akita, H | 1 |
| Satoh, T | 1 |
| Kudo, T | 1 |
| Homma, Y | 1 |
| Taniguchi, K | 1 |
| Murakami, T | 1 |
| Nakazawa, M | 1 |
| Matsuyama, R | 1 |
| Mori, R | 1 |
| Takeda, K | 1 |
| Ueda, M | 1 |
| Ichikawa, Y | 1 |
| Tanaka, K | 1 |
| Xue, P | 1 |
| Kanai, M | 1 |
| Mori, Y | 1 |
| Nishimura, T | 1 |
| Uza, N | 1 |
| Kodama, Y | 1 |
| Kawaguchi, Y | 1 |
| Takaori, K | 1 |
| Matsumoto, S | 1 |
| Uemoto, S | 1 |
| Chiba, T | 1 |
| Iida, T | 1 |
| Nakabayashi, Y | 1 |
| Okui, N | 1 |
| Shiba, H | 1 |
| Otsuka, M | 1 |
| Yanaga, K | 1 |
| Okabayashi, T | 1 |
| Shima, Y | 1 |
| Iwata, J | 1 |
| Morita, S | 1 |
| Sumiyoshi, T | 1 |
| Kozuki, A | 1 |
| Tokumaru, T | 1 |
| Iiyama, T | 1 |
| Kosaki, T | 1 |
| Kobayashi, M | 1 |
| Hanazaki, K | 1 |
| Amano, R | 1 |
| Kimura, K | 1 |
| Nakata, B | 1 |
| Yamazoe, S | 1 |
| Motomura, H | 1 |
| Yamamoto, A | 1 |
| Tanaka, S | 2 |
| Hirakawa, K | 1 |
| Yanagimoto, H | 3 |
| Sho, M | 1 |
| Kotsuka, M | 1 |
| Kinoshita, S | 1 |
| Nishiwada, S | 1 |
| Nagai, M | 1 |
| Ikeda, N | 1 |
| Tsuta, K | 1 |
| Nakajima, Y | 1 |
| Kon, M | 3 |
| Imamura, T | 1 |
| Ikoma, H | 1 |
| Morimura, R | 1 |
| Hatakeyama, T | 1 |
| Kosuga, T | 1 |
| Konishi, H | 1 |
| Murayama, Y | 1 |
| Komatsu, S | 1 |
| Shiozaki, A | 1 |
| Kuriu, Y | 1 |
| Nakanishi, M | 1 |
| Ichikawa, D | 1 |
| Fujiwara, H | 1 |
| Okamoto, K | 1 |
| Ochiai, T | 2 |
| Otsuji, E | 1 |
| Goto, T | 1 |
| Toyama, H | 1 |
| Asari, S | 1 |
| Terai, S | 1 |
| Kinoshita, H | 2 |
| Matsumoto, T | 1 |
| Kuramitsu, K | 1 |
| Tanaka, M | 1 |
| Takebe, A | 1 |
| Kido, M | 1 |
| Matsumoto, I | 1 |
| Ajiki, T | 1 |
| Fukumoto, T | 1 |
| Ku, Y | 1 |
| Honda, G | 2 |
| Kurata, M | 2 |
| Okuda, Y | 1 |
| Sakamoto, K | 1 |
| Karasawa, K | 1 |
| Chang, T | 1 |
| Egawa, N | 1 |
| Kamisawa, T | 1 |
| Omuro, Y | 1 |
| Tsuruta, K | 1 |
| Oba, A | 1 |
| Ban, D | 1 |
| Kirimura, S | 1 |
| Akahoshi, K | 1 |
| Mitsunori, Y | 1 |
| Matsumura, S | 1 |
| Kudo, A | 1 |
| Minoru, T | 1 |
| Ohe, C | 1 |
| Miyasaka, C | 1 |
| Uemura, Y | 1 |
| Michiura, T | 1 |
| Matsui, Y | 1 |
| Tanigawa, N | 1 |
| Tomihara, H | 1 |
| Tanemura, M | 1 |
| Takahara, N | 1 |
| Mizuma, M | 1 |
| Isayama, H | 1 |
| Kodera, Y | 1 |
| Ishigami, H | 1 |
| Kaneta, A | 1 |
| Tsuchiya, T | 1 |
| Saito, T | 1 |
| Otani, S | 1 |
| Ito, F | 1 |
| Miura, J | 1 |
| Kitasato, Y | 1 |
| Yasunaga, M | 1 |
| Nakayama, M | 1 |
| Akasu, G | 1 |
| Yoshitomi, M | 1 |
| Mikagi, K | 1 |
| Kawahara, R | 1 |
| Ishikawa, H | 1 |
| Hisaka, T | 1 |
| Horiuchi, H | 1 |
| Okabe, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial Comparing Nab-paclitaxel Plus S-1 Versus Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Patients With Advanced Pancreatic Cancer[NCT03636308] | Phase 2 | 40 participants (Anticipated) | Interventional | 2018-07-17 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for oxonic acid and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patients: A meta-analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carc | 2021 |
9 trials available for oxonic acid and Carcinoma, Ductal, Pancreatic
23 other studies available for oxonic acid and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancre | 2021 |
Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real-world data.
Topics: Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Humans; Japan; Oxonic Acid; Pancreas; Pancreat | 2023 |
Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real-world data.
Topics: Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Humans; Japan; Oxonic Acid; Pancreas; Pancreat | 2023 |
Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real-world data.
Topics: Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Humans; Japan; Oxonic Acid; Pancreas; Pancreat | 2023 |
Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real-world data.
Topics: Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Humans; Japan; Oxonic Acid; Pancreas; Pancreat | 2023 |
Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Drug Combinations; F | 2020 |
Combined ablation-chemotherapy versus chemotherapy alone for pancreatic cancer with liver metastasis: a propensity score matching study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Ther | 2021 |
Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, A | 2021 |
Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Ch | 2021 |
Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ducta | 2021 |
Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2021 |
The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone.
Topics: Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; | 2018 |
The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoma, | 2018 |
Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; | 2014 |
Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; | 2014 |
Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug | 2014 |
S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemo | 2014 |
Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2015 |
[The Clinical Efficacy of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Carcinoma--Report of Two Cases Treated by Curative Pancreatectomy with Portal Vein Resection after Neoadjuvant Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; | 2015 |
[A Case of Invasive Intraductal Papillary Mucinous Carcinoma, Penetrating the Stomach, Colon, and Jejunum].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Ad | 2015 |
Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Pancreatic Du | 2016 |
Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
Topics: Adult; Aged; Ascites; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuv | 2017 |
Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2017 |
[Pancreatic Adenosquamous Carcinoma That Developed after Resection of IPMA in the Pancreatic Tail].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Pancreati | 2016 |
[A case of peritoneal recurrence of invasive carcinoma derived from IPMN after distal pancreatectomy].
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Drug Combinat | 2011 |